SEP 08, 2017 1:46 PM PDT

Lipoxin: A New Drug for Heart Attack Recovery

WRITTEN BY: Kara Marker

More than half of all heart attack patients die within five years of the event. This is a frightening statistic, but University of Alabama at Birmingham scientists are focused on making that number smaller and making lives longer. In their most recent study, published in the journal Scientific Reports, researchers boost post-heart attack healing with a molecule called lipoxin.

According to the American Heart Association, cardiovascular disease is the underlying cause of death for nearly 1 in every 3 deaths in the United States.

Lipoxins are right in the middle of the action when it comes to the immune system and have been used to treat inflammatory disorders, renal fibrosis, and even cancer because of it. They are known to be anti-inflammatory, making them the perfect candidate for reducing chronic inflammation following a heart attack.

The immune response following a heart attack isn’t inherently harmful. The first wave is an acute inflammatory response, where white blood cells flow into the heart tissues to remove dead cells and begin building scar tissue to replace them. After this, the immune response begins the healing process.

These two reactions are normal and healthy. But when the initial stage of acute inflammation turns into chronic inflammation, that’s a problem. Over time, excessive inflammation leads to swelling in the heart’s left ventricle, ultimately resulting in congestive heart failure and death.

But in the new University of Alabama at Birmingham study, researchers found that giving mice a form of lipoxin called 15-epimer lipoxin A4, also known as “aspirin-trigger lipoxin A4,” improved heart function after a heart attack by boosting activity during the healing phase but leaving the acute inflammation phase alone. With this effect, lipoxin reveals its therapeutic potential as a post-heart attack treatment.

The research team started by inducing heart attacks in mice models, followed by a treatment of lipoxin. To see how it worked to improve heart function, they took observed and measured the following:

  • Heart function and swelling in the lungs

  • Spleen and kidney function (These organs are also affected by the initial acute immune response during a heart attack)

  • Neutrophil clearance during the healing phase (Neutrophils are first-responders in the immune system)

  • Activation or inhibition of macrophage receptors (Macrophages engulf and digest dead and dying cells)

  • Changes in pro-resolving gene markers in the left ventricle, spleen and kidneys

  • Changes in interleukin levels (Certain interleukins indicate changes in the immune system)

  • Transition of fibroblasts into secretory myofibroblasts (Fibroblasts deposit collagen, contribution to scarring)

Analysis of these parameters led them to the final conclusion that lipoxin successfully boosts heart function after a heart attack. First, researchers saw an improved ejection fraction, a measurement of how much blood is pushed out of the heart when it contacts. The better the ejection fraction, the more oxygenated blood is sent out into the body to provide tissues with oxygen and nutrients.

In addition, researchers saw active receptors on reparative macrophages and inhibited receptors on inflammatory macrophages. Lipoxin increased the number of neutrophils pushing their way into the heart during acute inflammation, and it promoted the clearance of neutrophils and reparative macrophages during the healing phase.

All things considered, lipoxin has a powerful and beneficial effect on the heart at a time when recovery is extremely vital, for the short-term and for the long-term.

Sources: MayoClinic, Journal of Inflammatory Research, University of Alabama at Birmingham

About the Author
  • I am a scientific journalist and enthusiast, especially in the realm of biomedicine. I am passionate about conveying the truth in scientific phenomena and subsequently improving health and public awareness. Sometimes scientific research needs a translator to effectively communicate the scientific jargon present in significant findings. I plan to be that translating communicator, and I hope to decrease the spread of misrepresented scientific phenomena! Check out my science blog: ScienceKara.com.
You May Also Like
MAR 18, 2021
Drug Discovery & Development
New Cancer Immunotherapy Targets Genetic Alteration in All Cancers
MAR 18, 2021
New Cancer Immunotherapy Targets Genetic Alteration in All Cancers
Researchers have developed a prototype for a new kind of cancer immunotherapy. The therapy uses engineered T-cells to ta ...
MAR 23, 2021
Microbiology
Pregnant Moms Easily Pass On COVID-19 Antibodies Through Placenta
MAR 23, 2021
Pregnant Moms Easily Pass On COVID-19 Antibodies Through Placenta
Recent work has shown that SARS-CoV-2 antibodies that are carried by a pregnant woman can cross the placenta and reach t ...
MAR 30, 2021
Neuroscience
Prolonged Amygdala Activity Predicts Personal Wellbeing
MAR 30, 2021
Prolonged Amygdala Activity Predicts Personal Wellbeing
Researchers have found that activity in the amygdala (the emotional center of the brain) following exposure to negative ...
APR 01, 2021
Health & Medicine
60 Percent of Texans Using Cannabis Prefer it Over Conventional Drugs
APR 01, 2021
60 Percent of Texans Using Cannabis Prefer it Over Conventional Drugs
A new survey out of Texas has revealed that 61 percent of people in the state who identify as medicinal cannabis users h ...
APR 05, 2021
Cannabis Sciences
Can Smoking Cannabis Cause Lung Cancer?
APR 05, 2021
Can Smoking Cannabis Cause Lung Cancer?
So far, there is no firm consensus on whether smoking cannabis can cause lung cancer. As cannabis smoke contains many si ...
APR 15, 2021
Immunology
COVID Vaccines Protect Breastfeeding Babies Too
APR 15, 2021
COVID Vaccines Protect Breastfeeding Babies Too
Good news for families of newborns: A new study shows that breastfeeding mothers who receive a COVID vaccine share prote ...
Loading Comments...